Volume Alert - OXGN 2.01 Oxigene Inc $OXGN Hit a high today

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 2:42 PM

Volume Alert - OXGN 2.01 Oxigene Inc $OXGN Hit a high today of 2.15 Closing the day 10:30 at 2.01 +0.03 +1.52% With a day low of 1.97 and a total volume of 871,476.

OXGN Recent Posts: http://investorshangout.com/OXiGENE-Inc-OXGN-55032/

OXGN Oxigene Inc Recent Headline News

Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?
Clinically Sound Investor - at Seeking Alpha - 2 hrs 58 mins ago

OXGN: 1.87 (-0.11)

OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated
Trevor Lowenthal - at Seeking Alpha - Fri Nov 14, 3:20PM CST

OXGN: 1.87 (-0.11)

Oxigene: Why I Think This Risky Biotech Is A Speculative Buy
Daniel Ward - at Seeking Alpha - Fri Nov 14, 8:15AM CST

OXGN: 1.87 (-0.11)

OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:27PM CST

OXGN: 1.87 (-0.11)

OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST

OXGN: 1.87 (-0.11)

OXiGENE beats by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:05PM CST

OXGN: 1.87 (-0.11)

OXiGENE Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:02PM CST
- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -
OXGN: 1.87 (-0.11)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:18AM CST

ANV: 1.60 (+0.23), KEP: 20.36 (-0.20), RADA: 2.38 (-0.17), SEAS: 16.96 (+0.05), HPJ: 6.10 (-0.13), PLUG: 3.71 (-0.01), SUPN: 8.35 (-0.12), NBG: 2.18 (-0.04), GV: 2.06 (+0.03), OXGN: 1.87 (-0.11), NOAH: 16.79 (-0.38), FOSL: 107.11 (-1.21), AEO: 13.52 (+0.02), IBIO: 1.09 (+0.04), MTOR: 14.08 (-0.02), MLNX: 42.42 (-0.48), SUSQ: 13.06 (-0.09)

Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data
at The Street - Wed Nov 12, 4:12AM CST
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
OXGN: 1.87 (-0.11), GSK: 45.86 (+0.12)

Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Tue Nov 11, 4:56AM CST

OXGN: 1.87 (-0.11)

Stock to Watch: OXiGENE Down 6.9% (OXGN)
Comtex SmarTrend(R) - Mon Nov 10, 11:59AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 6.9% to $2.01 on 1.0x average daily volume. Thus far today, OXiGENE has traded 694,000 shares, vs. average volume of 663,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.2%) and underperformed the S&P 500 (-6.9% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)

OxiGene presents Phase 2 data on fosbretabulin
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:31AM CST

OXGN: 1.87 (-0.11)

Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.03), IMGN: 9.25 (-0.28), AMGN: 159.37 (+1.69), LLY: 67.31 (-0.02), ONTX: 4.67 (-0.02), BMY: 58.40 (+0.45), GSK: 45.86 (+0.12), OXGN: 1.87 (-0.11), XLRN: 32.94 (-0.56), KPTI: 40.66 (+0.89), NVS: 94.42 (+0.47)

OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer
GlobeNewswire - Mon Nov 10, 2:00AM CST
- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients -
OXGN: 1.87 (-0.11)

OXiGENE Down 5.8%, Shares Slide into the Red (OXGN)
Comtex SmarTrend(R) - Thu Nov 06, 10:09AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 5.8% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 783,000 shares, vs. average volume of 600,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.5%) and underperformed the S&P 500 (-5.8% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)

Lower Your Expectations For OXiGENE's Presentation At The November 8 International Gynecologic Cancer Society Meeting
Clinically Sound Investor - at Seeking Alpha - Thu Nov 06, 9:15AM CST

OXGN: 1.87 (-0.11)

OXiGENE Up 5.6%, Shares Break Through Resistance (OXGN)
Comtex SmarTrend(R) - Mon Oct 27, 11:36AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's best performing low-priced stocks, up 5.6% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 594,000 shares, vs. average volume of 440,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's -0.2%) and outperformed the S&P 500 (5.6% to the S&P's -0.4%) during today's trading.
OXGN: 1.87 (-0.11)

Traders Get Bullish on Shares of OXiGENE, Shares Up 6.1% (OXGN)
Comtex SmarTrend(R) - Fri Oct 24, 10:08AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's best performing low-priced stocks, up 6.1% to $2.09 on 1.8x average daily volume. Thus far today, OXiGENE has traded 801,000 shares, vs. average volume of 447,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.3%) and outperformed the S&P 500 (6.1% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta
at The Street - Fri Oct 24, 7:28AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.87 (-0.11), RNA: 11.40 (+0.13), SRPT: 15.19 (-0.13), RMTI: 10.55 (+0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

VetsinTech's AI Training Boosts Military Careers

A New Spin on Engineering Careers Sometimes it feels like every corner I turn in this market maze, there’s something about AI. It’s not just chirping in the tech world anymore; it’s banging on the doors of sectors like engineering, aerospace, and manufacturing. And now, VetsinTech is tossing its hat into the AI ring with a fresh program aimed at blending military...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...